EDITEditas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest. | ||
 Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year. | ||
 EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data. | ||
 Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates Geron (GERN) delivered earnings and revenue surprises of -100.00% and +4.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||